STAT+: Pharma’s reputation with patient groups is sliding again thanks to prices and shortages
The pharmaceutical industry saw its reputation slip last year among patient advocacy groups thanks to growing concern about the rising prices for medicines and a lack of confidence prompted by increasing shortages, according to a new survey.
Of more than 2,500 groups queried, 57% reported that the industry maintained an “excellent” or “good” reputation as it goes about the business of developing and providing medicines. Although the findings suggest a clear majority of patients group are largely satisfied with drug companies, this represents a decline — albeit, a slight one — after several years in which the industry was seen more positively.
The previous survey found that 60% of the groups indicated the industry had an “excellent” or “good” reputation, which amounted to a substantial, year-over-year improvement from the 41% of the groups that expressed such a view in 2018. The steady increase was largely attributed to the initial response among many companies to quickly develop salves for the Covid-19 pandemic.
Continue to STAT+ to read the full story…
